Your shopping cart is currently empty

Kukoamine A possesses anticancer, cytoprotective, antioxidant, and anti-inflammatory activities, and inhibits trypanothione reductase as a mixed inhibitor (Ki = 1.8 microM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 2 mg | $76 | In Stock | In Stock | |
| 5 mg | $143 | In Stock | In Stock | |
| 10 mg | $259 | In Stock | In Stock | |
| 25 mg | $439 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $167 | In Stock | In Stock |
| Description | Kukoamine A possesses anticancer, cytoprotective, antioxidant, and anti-inflammatory activities, and inhibits trypanothione reductase as a mixed inhibitor (Ki = 1.8 microM). |
| Targets&IC50 | Trypanothione reductase:1.8 microM(Ki), LOX:9.5 microM |
| In vitro | The four possible regioisomers of Kukoamine A, as well as a series of Kukoamine A analogs incorporating changes in either the SPM or the DHCA structural units, were evaluated for their antioxidant activity and their inhibitory activity on soybean lipoxygenase (LOX) and lipid peroxidation[1]. The reducing properties of the compounds were evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging assay and found to be in the range 5-97.5%. Kukoamine A significantly inhibits LOX with IC50 9.5 microM. All tested analogs inhibited lipid peroxidation in the range of 11-100%[1]. |
| In vivo | Kukoamine A has neuroprotective effects through inhibiting oxidative stress and apoptosis after whole-brain irradiation (WBI) in rats[1]. |
| Molecular Weight | 530.66 |
| Formula | C28H42N4O6 |
| Cas No. | 75288-96-9 |
| Smiles | Oc1ccc(CCC(=O)NCCCNCCCCNCCCNC(=O)CCc2ccc(O)c(O)c2)cc1O |
| Relative Density. | 1.213 g/cm3 at 20℃ |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (113.07 mM), Sonication is recommended. H2O: 100 mg/mL (188.44 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.77 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.